Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection. - Wikidata - awgldk - TriplyDB

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

http://www.wikidata.org/entity/Q33362778

about

Discovery and characterization of vicriviroc (SCH 417690), a CCR5 antagonist with potent activity against human immunodeficiency virus type 1 HIV and the chemokine system: 10 years later.Chemokines and chemokine receptors: update on utility and challenges for the clinician.Concise Review: CXCR4/CXCL12 Signaling in Immature Hematopoiesis--Lessons From Pharmacological and Genetic Models Stroma-derived factor (SDF-1/CXCL12) and human tumor pathogenesis AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent Susceptibility of HIV-1 subtypes B', CRF07_BC and CRF01_AE that are predominantly circulating in China to HIV-1 entry inhibitors Identification of anti-malarial compounds as novel antagonists to chemokine receptor CXCR4 in pancreatic cancer cells The root extract of the medicinal plant Pelargonium sidoides is a potent HIV-1 attachment inhibitor A novel small-molecule inhibitor of HIV-1 entry i-bodies, Human Single Domain Antibodies That Antagonize Chemokine Receptor CXCR4.Closing the door to human immunodeficiency virus.Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.Sequential administration of the high affinity CXCR4 antagonist BKT140 promotes megakaryopoiesis and platelet production.Plerixafor plus granulocyte CSF can mobilize hematopoietic stem cells from multiple myeloma and lymphoma patients failing previous mobilization attempts: EU compassionate use data.Selective enhancement of donor hematopoietic cell engraftment by the CXCR4 antagonist AMD3100 in a mouse transplantation model.The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.Thermal stability of the human immunodeficiency virus type 1 (HIV-1) receptors, CD4 and CXCR4, reconstituted in proteoliposomes.Emerging concepts and approaches for chemokine-receptor drug discovery.Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases.Role of Chemokines and Chemokine Receptors in Prostate Cancer Development and Progression The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.Rapid mobilization of hematopoietic progenitors by AMD3100 and catecholamines is mediated by CXCR4-dependent SDF-1 release from bone marrow stromal cells.CXCR4 nanobodies (VHH-based single variable domains) potently inhibit chemotaxis and HIV-1 replication and mobilize stem cells.A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection.Novel compounds containing multiple guanide groups that bind the HIV coreceptor CXCR4.Maraviroc, a CCR5 coreceptor antagonist that blocks entry of human immunodeficiency virus type 1.Combined VEGF and CXCR4 antagonism targets the GBM stem cell population and synergistically improves survival in an intracranial mouse model of glioblastoma.Preclinical development of a novel class of CXCR4 antagonist impairing solid tumors growth and metastases The intricate role of CXCR4 in cancer.High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis CXCR4 Antagonists: A Screening Strategy for Identification of Functionally Selective Ligands.An important role of the SDF-1/CXCR4 axis in chronic skin inflammation HbAHP-25, an In-Silico Designed Peptide, Inhibits HIV-1 Entry by Blocking gp120 Binding to CD4 Receptor.CXCR4 Antagonism Attenuates the Development of Diabetic Cardiac Fibrosis.Process of hepatic metastasis from pancreatic cancer: biology with clinical significance.AMD3100 reduces CXCR4-mediated survival and metastasis of osteosarcoma by inhibiting JNK and Akt, but not p38 or Erk1/2, pathways in in vitro and mouse experiments.HIV-1 antiretroviral drug therapy.

P2860

Q24534620-C8A15305-AF7C-49CB-8632-E84C9D63D555 Q27473020-0E0F4905-0331-4D80-AE71-1D14DF00653C Q27687402-8C3878E0-6EC6-4FD7-8282-2B5F7D51DF67 Q28080830-57433A58-5CA2-4B41-9599-22ED10F8E1B2 Q28260997-B6D5F1EF-AEDE-45B5-8035-5B52A52A471D Q28286940-16E4D8B2-1038-4C38-910C-8FDFE0E9DC9E Q28477409-6B45F152-C751-4918-AA01-5B3757B093E4 Q28480517-17C873C9-7526-4CE4-980E-29B2FBD7AEA2 Q28539308-5F1EDAF0-0AB0-41F5-9AD3-1DDD23E6F2AF Q28606625-498ED9EF-3941-4B87-8316-DF071ECA43F7 Q30386356-CD96C494-9FBA-43E5-9DA0-708BD9322BAD Q30428089-451DA094-CA62-4653-816A-3213FEC4D86A Q30832371-AEFD06AA-3B45-4510-8721-1FD92C3497E5 Q33409463-FD8367A7-5A78-4B8E-9CBA-85A75E51CC67 Q33543723-97C14647-974D-46DB-B2BD-E2DD1960502D Q33623571-7C38C7AE-22C2-4AF7-9667-744DF48C228F Q33705883-C535E816-127E-4475-A73D-EF590B308704 Q33708995-52EE7FFC-AC42-4597-B883-3E85DBA639D1 Q33725587-9B2F0671-324C-4C67-8A5F-54744C8B063D Q33763369-70CB1CFE-C9E9-4629-82F5-082077EBFAD3 Q33886716-2FFBD5AB-694B-4A27-AE89-356F82BABAF5 Q34090617-123E482A-313D-4E08-A09C-3CEF596A5BC0 Q34213411-3A2D6D10-C8AB-451C-8C3C-5C25D03F45C5 Q34246928-29E3895F-1D78-4506-AFFB-5AD754F06A96 Q34377450-4C441DFE-A767-4B1F-BDA7-00FA5151AA50 Q34403975-CD1113C8-36C6-4CA8-A720-56D8F725F6E3 Q34473072-F417DCCA-72B5-481A-8BC8-3A8FD77AB294 Q34483653-BFDCA2A1-60CB-4D76-81A6-626A55147705 Q34604941-448A9770-1495-43E5-B322-26017EDA9BDC Q34654670-03B3FFC2-46FE-427F-AB53-99F80524B1A5 Q34994758-882E2243-19C3-48A8-8145-5DDD4D6309AF Q35067624-BD14BCB5-0726-4299-A8A8-92EA892E3E2A Q35070914-64542023-E755-4434-94B1-C3726E5B5E36 Q35121597-6005E9A7-EDEC-4D53-9809-3D0D2EC32C38 Q35138679-7EEA9CAD-A19D-464C-B218-710A09BB3B18 Q35542610-F8B009A1-483C-434A-A1B5-43B974FE0FF7 Q35716354-9E1EC051-86A2-4D58-9AAE-B31E78111C1F Q35739397-4AEE8D11-1FAB-48A0-BDDC-A30173677786 Q35794312-BEAA8348-76E1-4D0D-A863-9EAD006E5792 Q35853012-16AF308A-340E-468A-A66E-7B91EC621A6D

P2860

Safety, pharmacokinetics, and antiviral activity of AMD3100, a selective CXCR4 receptor inhibitor, in HIV-1 infection.

http://www.wikidata.org/entity/Q33362778

description

2004 nî lūn-bûn

@nan

2004 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Safety, pharmacokinetics, and ...... inhibitor, in HIV-1 infection.

@ast

Safety, pharmacokinetics, and ...... inhibitor, in HIV-1 infection.

@en

type

label

Safety, pharmacokinetics, and ...... inhibitor, in HIV-1 infection.

@ast

Safety, pharmacokinetics, and ...... inhibitor, in HIV-1 infection.

@en

prefLabel

Safety, pharmacokinetics, and ...... inhibitor, in HIV-1 infection.

@ast

Safety, pharmacokinetics, and ...... inhibitor, in HIV-1 infection.

@en

P1433

Q33362778-5B5F91EC-E1DC-480C-BB05-AC4D77F312BB

P1476

Q33362778-84111688-686F-4DCA-97AD-048359C24A13

P2093

Q33362778-28B1F6A4-F0EE-4B58-AC65-8382F7A4656C

Q33362778-35C573BC-A0AD-43B5-B368-AB621D810641

Q33362778-3AF94ACC-3D8E-4AF4-805F-4A6D236F5F7D

Q33362778-3E362E56-797F-4C0C-B719-8C6CAAE0AD42

Q33362778-3F6AB5B9-7E80-401A-B35F-C45F51D9A059

Q33362778-4C1B84EE-634F-448C-85B2-F4E102840C33

Q33362778-8B27F7F8-8510-431C-BDC3-F782F5ECBE29

Q33362778-8F1B228A-B0A0-49F8-9E88-E109842A0791

Q33362778-8FFC8609-00A9-4491-A151-5C1442161CF0

Q33362778-9944B648-16C4-40DF-A95F-E9DDA66AB953

P304

Q33362778-E07B000B-F3C2-454B-BD6A-FB6ADA9CA89C

P31

Q33362778-378861FB-3D79-4854-AD47-1E95A5142CB6

P356

Q33362778-0E0556D9-AB87-4F1A-B5D1-0F6F4084C2FB

P407

Q33362778-C0AEAC1E-0526-4319-8C34-AD47BA82DD70

P433

Q33362778-E59BA43A-17E2-438F-BB2C-11DCC99D9930

P478

Q33362778-9B19FB5C-DB05-4BBD-B5B2-3035BA92AA42

P50

Q33362778-58E40FF5-C1DA-4AE1-8818-C5DF95AF04C4

Q33362778-F20275D7-4D61-4B4B-A8FD-59D5AFF56908

P577

Q33362778-DBE076DC-B2C6-4C45-812F-DE1DBD0CE3B4

P698

Q33362778-4686F595-2ADE-438D-A31A-87A77A330BC2

P356

01.QAI.0000137371.80695.EF

P1433

Journal of Acquired Immune Deficiency Syndromes

P1476

Safety, pharmacokinetics, and ...... inhibitor, in HIV-1 infection

@en

P2093

AMD3100 HIV Study Group

http://www.w3.org/2001/XMLSchema#string

Ann C Collier

http://www.w3.org/2001/XMLSchema#string

Charles W Flexner

http://www.w3.org/2001/XMLSchema#string

Craig W Hendrix

http://www.w3.org/2001/XMLSchema#string

Gary Calandra

http://www.w3.org/2001/XMLSchema#string

Gary J Bridger

http://www.w3.org/2001/XMLSchema#string

Geoffrey W Henson

http://www.w3.org/2001/XMLSchema#string

Karin Badel

http://www.w3.org/2001/XMLSchema#string

Marshall J Glesby

http://www.w3.org/2001/XMLSchema#string

Michael M Lederman

http://www.w3.org/2001/XMLSchema#string

P304

1253-1262

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/01.QAI.0000137371.80695.EF

http://www.w3.org/2001/XMLSchema#string

P407

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

37

http://www.w3.org/2001/XMLSchema#string

P50

Dominique Schols

P577

2004-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15385732

http://www.w3.org/2001/XMLSchema#string